Overview: Lysozyme TestIntroduction: The Lysozyme Test measures lysozyme to diagnose leukemia or inflammatory diseases, causing fever or fatigue. Aligned with 2023 ASH guidelines, it uses immunoassay for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected leukemia or inflammatory conditions.
Other Names: Lysozyme Assay, Muramidase Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Lysozyme testing began in the 1960s with leukemia research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures lysozyme to diagnose leukemia or inflammatory diseases, guides treatment, and evaluates patients with fever or fatigue.
Test Parameters: 1. Lysozyme Level
Pretest Condition: No fasting required. Collect serum, plasma, or urine. Report history of fever, fatigue, or leukemia symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), Urine (sterile container, 5-20 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, fatigue, weight loss, or family history of leukemia or inflammatory diseases. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, leukemia or inflammatory disease implications, and risks of sample collection.
Procedural Considerations: Uses immunoassay to measure lysozyme in serum, plasma, or urine. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for leukemia or inflammatory disease diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Elevated lysozyme suggests leukemia (e.g., AML) or inflammatory diseases, guiding further evaluation or treatment. Normal levels may require additional testing.
Specialist Consultation: Consult a hematologist or rheumatologist for result interpretation and treatment planning.
Additional Supporting Tests: CBC, bone marrow biopsy, or CRP to confirm leukemia or inflammatory disease diagnosis.
Test Limitations: Not specific to one condition; other inflammatory states may elevate lysozyme. Clinical correlation is needed.
References: ASH Leukemia Guidelines, 2023; Blood, Döhner H, 2022.
